Second, the association between clinical response to the norepinephrine reuptake inhibitor reboxetine and late changes in HPA system activity (week 5) in our investigation is not confirmed by other clinical trials investigating the impact of reuptake inhibiting antidepressants on HPA axis function in depression, since the decrease in COR levels during serial DEX/CRH tests after 4 to 6 weeks of pharmacotherapy has been found to be comparable in responders and nonresponders in these studies [26]–[33]. The gene discussed is CRH; the disease is major depressive disorder.